

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO §240.13(d)-1(b), (c) and (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO §240.13d-2

---

**AquaBounty Technologies, Inc.**

(Name of Issuer)

**Common Stock, Par Value \$0.001 Per Share**

(Title of Class of Securities)

**UO387J108**

(CUSIP Number)

**December 30, 2016**

(Date of Event Which Requires Filing of this Statement)

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

CUSIP No. UO387J108

13G

1. Names of Reporting Persons  
Abbott Laboratories (I.R.S. Identification No. 36-0698440)

2. Check the Appropriate Box if a Member of a Group

- (a)   
(b)

3. SEC Use Only

4. Citizenship or Place of Organization  
Illinois

5. Sole Voting Power  
-0-

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

6. Shared Voting Power  
22,130,040

7. Sole Dispositive Power  
-0-

8. Shared Dispositive Power  
22,130,040

9. Aggregate Amount Beneficially Owned by Each Reporting Person

22,130,040

10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

11. Percent of Class Represented by Amount in Row (9)  
11.4%

12. Type of Reporting Person  
CO

2

CUSIP No. UO387J108

13G

1. Names of Reporting Persons  
CFR International SpA

2. Check the Appropriate Box if a Member of a Group

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization  
Chile

5. Sole Voting Power  
-0-

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

6. Shared Voting Power  
21,818,118

7. Sole Dispositive Power  
-0-

8. Shared Dispositive Power  
21,818,118

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
21,818,118

10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

11. Percent of Class Represented by Amount in Row (9)  
11.25%

12. Type of Reporting Person  
CO

3

**Item 1(a).** Name of Issuer:  
AquaBounty Technologies, Inc.

**Item 1(b).** Address of Issuer's Principal Executive Offices:

**Item 2(a) – (c).** Name, Address and Citizenship of Persons Filing:  
Abbott Laboratories  
100 Abbott Park Road  
Abbott Park, Illinois 60064  
United States

CFR International SpA  
Avenida Pedro de Valdivia No 295  
Comuna de Providencia  
Ciudad de Santiago Region Metropolitana  
7500524 Chile  
Chile

---

**Item 2(d).** Title of Class of Securities:  
Common Stock, par value \$0.001 per share

---

**Item 2(e).** CUSIP Number:  
UO387J108

---

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or (c), check which person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

**Item 4. Ownership.**

The information in items 1 through 12 on the cover pages (pages 2 and 3) of this statement is incorporated herein by reference.

**Item 5. Ownership of Five Percent or Less of a Class.**

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

CFR International SpA, a share corporation (*sociedad por acciones*) organized under the laws of Chile, is an indirect, wholly-owned subsidiary of Abbott Laboratories. The information regarding the shares of AquaBounty Technologies, Inc. held by CFR International SpA in items 1 through 12 on the cover pages (page 2) of this statement is incorporated herein by reference.

Western Pharmaceuticals SA, a corporation (*sociedad anónima*) organized under the laws of Ecuador and an indirect, wholly-owned subsidiary of Abbott Laboratories, holds an additional 311,922 shares of Common Stock of AquaBounty Technologies, Inc. Western Pharmaceuticals SA is subject to liquidation proceedings and voting and dispositive control over such shares is exercised by a liquidator appointed pursuant to Ecuadoran law.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

5

---

**Item 10. Certifications.**

Not applicable.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ABBOTT LABORATORIES

By: /s/ Brian B. Yoor\*  
Name: Brian B. Yoor  
Title: Senior Vice President, Finance and  
Chief Financial Officer

CFR INTERNATIONAL SpA

By: /s/ Brian B. Yoor\*  
Name: Brian B. Yoor  
Title: Authorized Signatory

\* By John A. Berry, Attorney-in-Fact.

6

---

**EXHIBIT A**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, Abbott Laboratories, an Illinois corporation, CFR International SpA, a share corporation (*sociedad por acciones*) organized under the laws of Chile, agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any amendments thereto) with respect to the Common Stock of AquaBounty Technologies, Inc., and further agree that this Agreement be included as an exhibit to such joint filing.

This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together shall constitute one and the same instrument.

The undersigned, being duly authorized, hereby execute this Agreement this December 30, 2016.

ABBOTT LABORATORIES

By: /s/ Brian B. Yoor\*  
Name: Brian B. Yoor  
Title: Senior Vice President, Finance and Chief Financial Officer

CFR INTERNATIONAL SpA

By: /s/ Brian B. Yoor\*  
Name: Brian B. Yoor  
Title: Authorized Signatory

\* By John A. Berry, Attorney-in-Fact

7

---

